Clinical Trial Search

Primary: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs) — 3; 9 Participants

Primary: Proportion of Participants Who Experience Worsening of Asthma by Week 24 — 0.658; 0.567; 0.568; 0.557 proportion of participants — p=0.1425

Primary: Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs — 44; 5; 43; 1 Participants

Primary: Change From Baseline in Total Subepithelial Eosinophils at the End of Week 78 (End of Treatment) — -5.807; -5.890; 1.555; -5.626 cells/mm^2

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059

Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800

Primary: Response to IL5/IL5R Antagonist — 76.5; 82.5 Percent

Primary: Asthma Exacerbations During 52 Weeks Preceding Treatment Initiation (as Assessed at Baseline) and at the 24th and 52nd Week of the Treatment — 3; 0; 0 number of asthma…

Primary: Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period — 39.1; 10.5 Liters/minute (L/min) — p=<0.001

Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 1.11; 0.46 Exacerbation per participant per year — p=< 0.001

Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…

Primary: Annual Asthma Exacerbation Rate (AERR) — 0.42; 1.63 Events per year — p=<0.001

Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001

Primary: The Percentage of Patients With Loss of Asthma Control — 17 Participants

Primary: Change in Number of Exacerbations of the Participants — 2.77; 1.32 Change in number of courses of oral c

Primary: Fractional Exhaled Nitric Oxide (FeNO) — 8.67; 9.01 parts per billion (ppb)

Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants

Primary: Safety of Osimertinib — 60 Participants

Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001

Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 0.56; 1.08 Exacerbation per participant per year — p=<0.001

Primary: Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85) — 2.190; 2.216; 2.110 Liters

Primary: 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 — 0.229; 0.157; 0.274 Liter — p=0.003

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001

Primary: Number of Participants With Change in Sputum Markers by End of Study — 0; 0 Participants

Primary: Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period — 0.151; 0.168; 0.605 Proportion of Participants

Primary: Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of Treatment — 0.52; 0.41 events — p=0.194

Primary: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) — 0.94; 1.86 Events/year — p=<0.0001

Primary: Number of Treatment Emergent Adverse Events — 6; 1; 7 Participants

Primary: Airway Resistance at 5 Hz (R5) at Baseline (Pre-mepolizumab Initiation) — 0.51; 0.39; 0.43 kPa/L/s

Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI